Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ordopidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.42 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | HTR6 | P50406 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ordopidine SCHEMBL2370525 | 0.99 | DRD3 (0.46) | DRD3HTR6HRH3DRD2SIGMAR1 | |
| Ordopidine SCHEMBL30522152 | 0.99 | DRD3 (0.46) | DRD3HTR6HRH3DRD2SIGMAR1 | |
| SCHEMBL13304588 | 0.95 | DRD3 (0.44) | DRD3HTR6HRH3DRD2SIGMAR1 | |
| SCHEMBL2783233 | 0.90 | DRD2 (0.55) | DRD3HTR6DRD2SIGMAR1SLC6A4 | |
| SCHEMBL13815538 | 0.87 | SIGMAR1 (0.47) | DRD3HTR6DRD2SIGMAR1SLC6A4 | |
| Ordopidine SCHEMBL5506147 | 0.86 | HTR6 (0.38) | DRD3HTR6HRH3DRD2SIGMAR1 | |
| SCHEMBL2783693 | 0.86 | KDM4E (0.38) | DRD3HTR6HRH3DRD2SIGMAR1 | |
| SCHEMBL2784849 | 0.86 | DRD3 (0.45) | DRD3HTR6HRH3DRD2SIGMAR1 | |
| SCHEMBL2783821 | 0.86 | DRD3 (0.45) | DRD3HTR6HRH3DRD2SLC6A4 | |
| SCHEMBL2781820 | 0.85 | HTR6 (0.48) | DRD3HTR6HRH3DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1997630-B | New disubstituted phenylpiperidines as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB | 2013-01-30 | — | — | CN | claimed |
| WO-2011107583-A1 | SUBSTITUTED 4-PHENYL-N-ALKYL-PIPERIDINES FOR PREVENTING ONSET OR SLOWING PROGRESSION OF NEURODEGENERATIVE DISORDERS | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-09-09 | — | — | WO | claimed |
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | claimed |
| US-7763639-B2 | Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-07-27 | — | — | US | claimed |
| EP-1773772-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-06-02 | — | — | EP | claimed |
| CN-1997630-A | New disubstituted phenylpiperidines as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2007-07-11 | — | — | CN | claimed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-1997630-B | New disubstituted phenylpiperidines as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB | 2013-01-30 | — | — | CN | disclosed |
| US-8314126-B2 | Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-11-20 | — | — | US | disclosed |
| US-8314126-B2 | Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-11-20 | — | — | US | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
| EP-1773772-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006040156-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NEUROSEARCH SWEDEN AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005121087-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121087-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885DRD3 4/4885HTR6 95/4885 |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885DRD3 4/4885HTR6 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.